​Dr Dama is a molecular oncology scientist and translational innovator with over 20 years of experience in cancer research, gene therapy, immunotherapy, and human-relevant preclinical science. She serves as Founder & CEO of NAMina Bio, leading strategic scientific integration across translational partners, AI platforms, and organ-on-chip technologies.

Dr. Dama holds a Master’s degree in Cellular Biology and a Doctorate in Molecular Oncology. Her work bridges rigorous biology, ethical innovation, and clinically relevant translational strategy.

She serves on the editorial boards of Cancer Gene Therapy (Nature Portfolio) and Frontiers in Transplantation, Cell and Stem Cell, and is the founder of Task Force Pandora, a scientific advocacy initiative focused on environmental health and public trust in science.

Editor-in-Chief, Cancer Gene Therapy (Nature Portfolio)

​

Dr. Leandro Castellano is a molecular biologist specializing in RNA biology and cancer. He obtained his PhD in Human Biology and Genetics from the University of Rome “La Sapienza” and has held academic positions at Imperial College London and the University of Sussex.

He is currently Head of the Department of Biochemistry and Biomedicine and Reader (Associate Professor) in RNA Biology at the University of Sussex, co-Director of the Sussex RNA Research Centre, and holds an honorary position at Imperial College London. His research focuses on microRNAs and non-coding RNAs in epithelial cancer development and progression.

He serves as Editor-in-Chief of Cancer Gene Therapy (Nature Portfolio).

​​Dr. Stefano Gaburro is the European Business Manager at Microbiologics and former Scientific Director at Tecniplast, with over 18 years of experience in neuropharmacology and laboratory animal science. His work sits at the intersection of translational research, digital technologies, and experimental system design.

He has specialized in the development and implementation of digital biomarkers to enhance animal welfare and experimental rigor, contributing to the evolution of more predictive and ethically grounded research models. His approach strongly aligns with the principles of the 3Rs (Replacement, Reduction, Refinement), advancing strategies that improve both the living conditions of laboratory animals and the quality of scientific outcomes.

​Eduardo Farias is a seasoned cell biologist and biotech leader with more than 35 years of experience translating scientific discoveries from concept toward clinical development. His expertise spans tumor progression biology, minimal residual disease, tumor dormancy, idiopathic pulmonary fibrosis, preclinical model development, and validation of innovative disease models, including advanced 3D in vitro systems and in vivo preclinical models.

As Founder & CEO of BioSolutions Consulting LLC, he supports biotechnology and pharmaceutical companies with strategic guidance across translational research, preclinical development, disease-model validation, and therapeutic program advancement. His experience provides NAMina Bio with important perspective on regulatory-aware study design, translational validation frameworks, and the development of human-relevant models aligned with drug-development decision-making.

​Dr. Alessandro Lagana' is an Assistant Professor of Oncological Sciences and Genetics and Genomic Sciences at the Icahn School of Medicine at Mount Sinai.

His research interests lie primarily in the area of integrative cancer genomics, cancer network biology and precision oncology, with particular focus on Multiple Myeloma, a malignancy of bone marrow plasma cells.

Alessandro achieved his MS degree in Computer Science and PhD in Biology, Human Genetics and Bioinformatics at the University of Catania (Italy), under the supervision of Alfredo Ferro, and completed his Post-Doctoral studies in Carlo Croce’s Lab at The Ohio State University in Columbus, OH, where his research focused primarily on microRNA.

Tim Mikhelashvili is a senior pharma leader, speaker, and Board member with 21 years of experience in Medical Affairs across 7 large, small and specialty companies, author of late-breaking head-to-head clinical and proof-of-principle, mechanistic, mechanistic publications at international scientific conferences that directly generated significant shareholder value of startup pharma companies competing against market leading drug manufacturers, transformed product launches and patient access to next-generation medications.

He is CEO of Amedea Pharma, a life science analytics agency dedicated to raising new standards of healthcare quality, and holds an MIT Certification in Leading Organizations and Change.

Tim’s contributions span building Learning and Development capabilities, transforming operations, company culture initiatives, CRM optimization, Medical Insights systems, mentorship and leadership development programs.

He is an industry innovator and entrepreneur, host of the @Alloutcoach leadership podcast and annual global healthcare competition, Medical Innovation Olympics since 2022.